Gilead HIV Combo Beats Glaxo Drug in Trial (Reuters)
Reuters - Gilead Sciences on Thursday said
preliminary data from a 48-week trial show that two of its two
drugs, Viread and Emtriva, were better able to control levels
of HIV than Combivir, a popular treatment sold by
GlaxoSmithKline Plc.
Read more...